GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (FRA:4QG) » Definitions » Retained Earnings

PCI Biotech Holding ASA (FRA:4QG) Retained Earnings : €0.00 Mil (As of Jun. 2023)


View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. PCI Biotech Holding ASA's retained earnings for the quarter that ended in Jun. 2023 was €0.00 Mil.

PCI Biotech Holding ASA's quarterly retained earnings increased from Dec. 2022 (€-5.22 Mil) to Mar. 2023 (€0.00 Mil) but then stayed the same from Mar. 2023 (€0.00 Mil) to Jun. 2023 (€0.00 Mil).

PCI Biotech Holding ASA's annual retained earnings increased from Dec. 2021 (€-44.21 Mil) to Dec. 2022 (€-5.22 Mil) and increased from Dec. 2022 (€-5.22 Mil) to Dec. 2023 (€0.00 Mil).


PCI Biotech Holding ASA Retained Earnings Historical Data

The historical data trend for PCI Biotech Holding ASA's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA Retained Earnings Chart

PCI Biotech Holding ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -30.65 -35.23 -44.21 -5.22 -

PCI Biotech Holding ASA Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -5.22 - - -

PCI Biotech Holding ASA Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


PCI Biotech Holding ASA  (FRA:4QG) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


PCI Biotech Holding ASA (FRA:4QG) Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The PCI technology works by inducing light-triggered endosomal release. PCI is applied to three distinct anticancer paradigms; fimaCHEM which is an enhancement of chemotherapeutics for localized treatment of cancer, fimaVACC which is T-cell induction technology for therapeutic vaccination, and fimaNAc which is nucleic acid therapeutics delivery. Its therapeutic product candidate is the photosensitizer fimaporfin (Amphinex) which can unlock the intracellular capsules where active compounds are trapped.

PCI Biotech Holding ASA (FRA:4QG) Headlines

No Headlines